Difference between Role of Nebulized Salbutamol and Nebulized Normal Saline in Treatment of Transient Tachypnea of New Born

Hajra Iqbal Alvi; Sohail Ashraf; Hassan Iqbal Alvi; Yumna Zafar; Ayesha Naseem

doi:10.70749/ijbr.v3i3.798

Authors

Hajra Iqbal Alvi Department of Pediatrics, POF Hospital, Wah Cantt, Pakistan.
Sohail Ashraf Department of Pediatrics, POF Hospital, Wah Cantt, Pakistan.
Hassan Iqbal Alvi Department of Pediatrics, POF Hospital, Wah Cantt, Pakistan.
Yumna Zafar Department of Pediatrics, POF Hospital, Wah Cantt, Pakistan.
Ayesha Naseem Department of Pediatrics, POF Hospital, Wah Cantt, Pakistan.

DOI:

https://doi.org/10.70749/ijbr.v3i3.798

Keywords:

Transient Tachypnea of the Newborn, Nebulized Salbutamol, Respiratory Rate, Beta-agonist, Treatment Efficacy

Abstract

Background: Transient Tachypnea of the Newborn (TTN) is a common respiratory condition in neonates, characterized by rapid breathing due to delayed lung fluid clearance. Nebulized Salbutamol, a beta-agonist, is a potential treatment for improving respiratory outcomes. Objective: To compare the mean respiratory rate with inhaled salbutamol and normal saline in transient tachypnea of new born. Study Design: Randomized controlled trial. Duration and Place of Study: The study was conducted at the Department of Pediatrics, POF Hospital Wah Cantt, from June 2023 to December 2023. Methodology: A total of 60 neonates with TTN were randomly assigned to two groups: Group A (Salbutamol) and Group B (Normal Saline). Patients were assessed for respiratory rate before treatment and at intervals of 30 minutes, 60 minutes, and 4 hours after nebulization. The main outcome measure was the change in respiratory rate at 4 hours’ post-treatment. Results: At baseline, the respiratory rates were similar in both groups: 77.00 ± 2.03 BPM in Group A and 76.90 ± 1.84 BPM in Group B (p = 0.843). At 30 minutes post-treatment, respiratory rates remained similar: Group A (72.17 ± 1.68 BPM) vs. Group B (72.37 ± 1.51 BPM, p = 0.631). At 60 minutes, no significant difference was observed: Group A (69.80 ± 1.76 BPM) vs. Group B (70.10 ± 1.70 BPM, p = 0.507). However, at 4 hours, Group A showed a significant improvement with a respiratory rate of 60.83 ± 1.62 BPM, while Group B had 76.27 ± 1.08 BPM (p < 0.001). Conclusion: Our study has demonstrated that nebulized Salbutamol is an effective treatment for reducing respiratory rates in neonates with TTN, with significant improvement observed at 4 hours post-treatment compared to normal saline.

Downloads

Download data is not yet available.

References

Neri, C., Sartorius, V., & De Luca, D. (2025). Transient tachypnoea: New concepts on the commonest neonatal respiratory disorder. European Respiratory Review, 34(175), 240112. https://doi.org/10.1183/16000617.0112-2024

Gupta, N., Bruschettini, M., & Chawla, D. (2021). Fluid restriction in the management of transient tachypnea of the newborn. Cochrane Database of Systematic Reviews, 2021(2). https://doi.org/10.1002/14651858.cd011466.pub2

Bruschettini, M., Hassan, K., Romantsik, O., Banzi, R., Calevo, M. G., & Moresco, L. (2022). Interventions for the management of transient tachypnoea of the newborn - an overview of systematic reviews. Cochrane Database of Systematic Reviews, 2022(2). https://doi.org/10.1002/14651858.cd013563.pub2

Chavan, S., Malwade, S. D., Kumari, S., Garud, B. P., & Agarkhedkar, S. (2022). Incidence, clinical features, and outcomes of transient tachypnea of the newborn at a tertiary care center in western India. Cureus. https://doi.org/10.7759/cureus.23939

McGillick, E. V., Te Pas, A. B., Van den Akker, T., Keus, J. M., Thio, M., & Hooper, S. B. (2022). Evaluating clinical outcomes and physiological perspectives in studies investigating respiratory support for babies born at term with or at risk of transient tachypnea: A narrative review. Frontiers in Pediatrics, 10. https://doi.org/10.3389/fped.2022.878536

Bruschettini, M., Moresco, L., Calevo, M. G., & Romantsik, O. (2020). Postnatal corticosteroids for transient tachypnoea of the newborn. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd013222.pub2

Madajczak, D., Daboval, T., Lauterbach, R., Łoniewska, B., Błaż, W., Szczapa, T., Sadowska-Krawczenko, I., Michalak-Kloc, M., Sławska, H., Borszewska-Kornacka, M., & Bokiniec, R. (2023). Protocol for a multicenter, double-blind, randomized, placebo-controlled phase III trial of the inhaled β2-adrenergic receptor agonist salbutamol for transient tachypnea of the newborn (the REFSAL trial). Frontiers in Pediatrics, 10. https://doi.org/10.3389/fped.2022.1060843

Choobdar, F. A., Vahedi, Z., Mazouri, A., Torkaman, M., Khosravi, N., Khalesi, N., Soltani, Z., Mohazzab, A., & Ashkanipour, R. (2024). Safety and efficacy of 2.5 mg and 1.25 mg nebulized salbutamol compared with placebo on transient tachypnea of the newborns: A triple-blind phase II/III parallel randomized controlled trial. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 37(4), 180-188. https://doi.org/10.1089/jamp.2023.0043

Basiri, B., Sadeghi, N., Sabzehei, M. K., & Ashari, F. E. (2022). Effects of inhaled salbutamol on transient tachypnea of the newborn. Respiratory Care, 67(4), 433-439. https://doi.org/10.4187/respcare.09284

Dhaka, A., Kumar, S., Singh, P., Priyadarshi, M., Chaurasia, S., Bhat, N. K., & Basu, S. (2024). Nebulized salbutamol for the treatment of transient tachypnea of the newborn: A randomized controlled trial. Journal of Perinatology. https://doi.org/10.1038/s41372-024-02201-0

Gipsman, A. I., Bhandari, A., & Bhandari, V. (2024). Use of mucolytics and inhaled antibiotics in the NICU. Journal of Perinatology, 45(1), 5-12. https://doi.org/10.1038/s41372-024-02178-w

Guellec, I., Debillon, T., Flamant, C., Jarreau, P., Serraz, B., & Tourneux, P. (2023). Management of respiratory distress in moderate and late preterm infants: Clinical trajectories in the Neobs study. European Journal of Pediatrics, 182(12), 5661-5672. https://doi.org/10.1007/s00431-023-05259-8

Salama, A., El-Seheim), L., & Elsamanoudy, M. (2020). Inhaled salbutamol for the treatment of transient tachypnea of the newborn. International Journal of Medical Arts, 2(2), 457-461. https://doi.org/10.21608/ijma.2020.21436.1064

Babaei, H., Dabiri, S., Leila, M. P., & Mohsenpour, H. (2019). Effects of Salbutamol on the Treatment of Transient Tachypnea of the Newborn. Iranian Journal of Neonatology IJN, 10(1), 42–49. https://doi.org/10.22038/ijn.2018.31294.1430

Ahmed, W., Tahir, A. M., Subhani, F. A., Ahmed, Z., Sohail, A., & Javed, H. (2022). Role of salbutamol in the management of transient tachypnea of the newborn: A comparative prospective study. Pakistan Armed Forces Medical Journal, 72(5), 1501-05. https://doi.org/10.51253/pafmj.v72i5.4746

Malakian, A., Dehdashtian, M., Aramesh, M. R., Aletayeb, M. H., & Heidari, S. (2018). The effect of inhaled salbutamol on the outcomes of transient tachypnea of the newborn. Journal of the Chinese Medical Association, 81(11), 990-997. https://doi.org/10.1016/j.jcma.2018.01.015

Moresco, L., Bruschettini, M., Macchi, M., & Calevo, M. G. (2021). Salbutamol for transient tachypnea of the newborn. Cochrane Database of Systematic Reviews, 2021(2). https://doi.org/10.1002/14651858.cd011878.pub3